Your browser doesn't support javascript.
loading
Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review.
Sodré-Alves, Bárbara Manuella Cardoso; Toledo, Melina Mafra; Zimmermann, Ivan Ricardo; Araújo, Wildo Navegantes de; Tavares, Noemia Urruth Leão.
Afiliação
  • Sodré-Alves BMC; Universidade de Brasília, Laboratório de Estudos Farmacêuticos, Brasília, DF, Brasil.
  • Toledo MM; Universidade de Brasília, Programa de Pós-Graduação em Ciências Farmacêuticas, Brasília, DF, Brasil.
  • Zimmermann IR; Universidade de Brasília, Programa de Pós-Graduação em Saúde Coletiva, Brasília, DF, Brasil.
  • Araújo WN; Universidade de Brasília, Laboratório de Estudos Farmacêuticos, Brasília, DF, Brasil.
  • Tavares NUL; Universidade de Brasília, Programa de Pós-Graduação em Saúde Coletiva, Brasília, DF, Brasil.
Rev Soc Bras Med Trop ; 57: e004022024, 2024.
Article em En | MEDLINE | ID: mdl-38536998
ABSTRACT

BACKGROUND:

The treatment strategy for latent tuberculosis infection is to reduce the number of tuberculosis cases and consequently reduce the transmission of pathogenic bacteria. This study aimed to determine the safety, effectiveness, and adherence of isoniazid use for latent tuberculosis infection treatment.

METHODS:

To identify studies on isoniazid use for latent tuberculosis infection, five electronic databases were searched. The methods and results are presented in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

RESULTS:

Most studies (53) used isoniazid for 9 months. The prevalence of use and adherence to treatment varied considerably (18% to 100%), and were evaluated by participant completion of isoniazid treatment for latent tuberculosis infection. The adverse events most frequently reported were hepatotoxicity, gastric intolerance, and neuropathy; the rates of occurrence ranged from < 1% to 48%. In the studies that evaluated the effectiveness of isoniazid for latent tuberculosis infection, the rate varied from 0 to 19.7% for patients who did not have active tuberculosis after the follow-up period.

CONCLUSIONS:

The importance of maintaining follow up for patients using isoniazid should be emphasized due to the risk of developing adverse events. Despite the treatment challenges, the rates of patients who used isoniazid and developed active tuberculosis during the follow-up period were low. We believe that isoniazid continues to contribute to tuberculosis control worldwide, and better care strategies are required.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Latente / Isoniazida / Antituberculosos Limite: Humans Idioma: En Revista: Rev Soc Bras Med Trop Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Latente / Isoniazida / Antituberculosos Limite: Humans Idioma: En Revista: Rev Soc Bras Med Trop Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil